Is dopamine antagonism a requisite of neuroleptic activity?
Neuroleptic activity in laboratory animals is characterized by a decrease in locomotor activity, ptosis, catalepsy, antagonism of certain amphetamine-induced responses, and inhibition of a conditioned avoidance response. Neuroleptics have also been shown to be potent antagonists of dopamine (DA), cis-5,6-Dimethoxy-2-methyl-3-[2-(4-phenyl-1-piperazinyl)-ethyl]indoline (DHO) has been shown to possess the above described pharmacological profile. However, in contrast to known neuroleptics, DHO has no effect on DA levels, DA turnover rate or DA-stimulated cyclase; nor did it have an effect on tyrosine hydroxylase activity. In addition, DHO did not antagonize apomorphine-induced gnawing or amphetamine-induced stereotyped behavior, both of which have been reported to be DA-dependent. However, the agent decreased the level of norepinephrine in the forebrain. An attempt is made to demonstrate that the "DA-hypothesis" of schizophrenia may not be valid in all cases, and that the biochemistry of the disease state is very complex.